Relmada Therapeutics (RLMD) Accounts Payables (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Accounts Payables data on file, last reported at $5.7 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $5.7 million, up 353.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (up 353.07% YoY), and the FY2025 annual result was $1.6 million, down 62.02% from the prior year.
• Accounts Payables climbed to $5.7 million in Q1 2026 per RLMD's latest filing, from $1.6 million in the prior quarter.
• Over five years, Accounts Payables peaked at $10.7 million in Q1 2022 and troughed at $1.3 million in Q1 2025.
• A 5-year average of $4.5 million and a median of $4.2 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables tumbled 75.62% in 2025, then jumped 353.07% in 2026.
• A 5-year view of Accounts Payables shows it stood at $5.3 million in 2022, then sank by 33.37% to $3.5 million in 2023, then gained by 17.81% to $4.1 million in 2024, then tumbled by 62.02% to $1.6 million in 2025, then surged by 265.3% to $5.7 million in 2026.
• Business Quant data shows RLMD's Accounts Payables at $5.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.5 million in Q3 2025.